Clinical trials
Bone Cancer Metastatic clinical trials
Below are recruiting bone cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 740 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06615752RecruitingPhase 1/Phase 2
Green tea and quercetin with chemo for prostate cancer
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06679036RecruitingPhase 1/Phase 2
Combination therapy for advanced breast cancer
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
Harbin, HeilongjiangAges 18–75 - NCT06733038RecruitingPhase 3
Chemo plus Avastin with or without Tecentriq for advanced colorectal cancer
This trial tests whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (FOLFOXIRI) and bevacizumab (Avastin) is more effective as a first treatment for people with a specific type of metastatic colorectal cancer that has a high immune score and is mismatch repair proficient.
Brescia, BSAges 18–75 - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT05168618RecruitingPhase 2
Cabozantinib and atezolizumab for advanced prostate cancer
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
Salt Lake City, UtahAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT07660276Enrolling by invitation
AI predicts prostate cancer spread from biopsy
This study uses an artificial intelligence (AI) system to look at prostate biopsy samples and predict if the cancer has spread to the lymph nodes. It may help doctors decide on the best treatment without needing extra surgery or scans.
Changsha, HunanAges 18–90 - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT07173868Recruiting
PET scans for advanced breast cancer treatment planning
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Seoul, Gannam-guAges 19 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT06479239RecruitingPhase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Charlottesville, VirginiaAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Tucson, ArizonaAges 18 years+ - NCT05305924RecruitingPhase 2
Fulvestrant plus abemaciclib for ER+, HER2− advanced breast cancer
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Houston, TexasAges 18 years+ - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT05420779RecruitingPhase 2
TSL-1502 for breast cancer with BRCA gene mutations
This Phase 2 trial tests TSL-1502 capsules, a targeted medicine for breast cancer, in people whose blood test shows a harmful BRCA gene mutation. It aims to see whether it can control the cancer and how safe it is after prior treatment.
BeijingAges 18–75 - NCT07481799RecruitingPhase 3
Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Zhuhai, GuangdongAges 18–75
Hear when a new Bone Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone cancer metastatic?
- Yes. Clin2 currently lists 740 recruiting bone cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.